Skip to main content

Advertisement

SpringerLink
Log in

The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review

  • Review
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

This scoping review aims to characterize the use of biologics and Janus Kinase inhibitors (JAKi) in the treatment of Hidradenitis Suppurativa (HS), which is a chronic inflammatory condition. A comprehensive literature search was conducted in PubMed/NCBI, Embase, Web of Science databases, and the Clinicaltrials.gov register. The search included interventional trials assessing the use of biologics or JAKi in HS, with no geographic or time restrictions. Secukinumab and adalimumab were identified as the only two drugs approved by the FDA for treating moderate to severe HS in adults. Several other drug classes showed promising results based on clinical studies reviewed. IL-12/23 inhibitor ustekinumab demonstrated improvements in disease severity scores and HiSCR rates in small trials. IL-17 inhibitors such as brodalumab, bimekizumab, and CJM112 showed preliminary positive responses in early-phase clinical studies and case reports. While evidence was mixed, some TNF-α inhibitors such as infliximab provided benefits according to a randomized controlled trial, though etanercept trials yielded non-significant or inconsistent findings. Larger, well-designed studies are required to further establish their efficacy and safety, but biologics and JAKis show potential as alternative treatment options for moderate to severe HS. The findings of this review contribute to the growing interest among patients and to enhancing the understanding of physician’s regarding potential alternative therapeutic options for HS and provide a basis for further research in this field.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

No datasets were generated or analysed during the current study.

References

  1. Vinkel C, Thomsen SF (2018) Hidradenitis suppurativa: causes, features, and current treatments. J Clin Aesthetic Dermatology 11(10):17–23

    Google Scholar 

  2. Kozera EK, Lowes MA, Hsiao JL, Frew JW (2021) Clinical considerations in the management of hidradenitis suppurativa in women[Formula presented]. Int J Women’s Dermatology 7(5):664–671

    Article  Google Scholar 

  3. Garg A, Lavian J, Lin G, Strunk A, Alloo A (2017) Incidence of hidradenitis suppurativa in the United States: a sex-and age-adjusted population analysis. J Am Acad Dermatol 77(1):118–122

    Article  PubMed  Google Scholar 

  4. Napolitano M, Megna M, Timoshchuk EA, Patruno C, Balato N, Fabbrocini G et al (2017) Hidradenitis suppurativa: from pathogenesis to diagnosis and treatment. Clinical, cosmetic and investigational dermatology. :105 – 15

  5. Sabat R, Jemec GBE, Matusiak Ł, Kimball AB, Prens E, Wolk K (2020) Hidradenitis suppurativa. Nat Reviews Disease Primers. ;6(1)

  6. Markota Čagalj A, Marinović B, Bukvić Mokos Z (2022) New and emerging targeted therapies for Hidradenitis Suppurativa. Int J Mol Sci. ;23(7)

  7. Flood KS, Porter ML, Kimball AB (2019) Biologic Treatment for Hidradenitis Suppurativa. Am J Clin Dermatol 20(5):625–638

    Article  PubMed  Google Scholar 

  8. Kyriakou A, Trigoni A, Galanis N, Sotiriadis D, Patsatsi A (2018) Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: real life data. Dermatol Rep 10(2):7859

    Article  Google Scholar 

  9. Kimball AB, Jemec GB, Alavi A, Reguiai Z, Gottlieb AB, Bechara FG et al (2023) Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 401(10378):747–761

    Article  CAS  PubMed  Google Scholar 

  10. Kimball AB, Alavi A, Jemec GB, Gottlieb A, Wei X, Wozniak MB et al (2023) Secukinumab in moderate to severe hidradenitis suppurativa: primary endpoint analysis from the SUNSHINE and SUNRISE phase 3 trials. SKIN J Cutan Med 7(2):s129–s

    Article  Google Scholar 

  11. Novartis P, Novartis Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) 2021 [updated October 2022. https://ClinicalTrials.gov/show/NCT03713632

  12. Novartis P, Novartis This is a Study of Efficacy and Safety of Two Secukinumab Dose Regimens in Subjects With Moderate to Severe Hidradenitis Suppurativa (HS) 2021 [updated January 2023. https://ClinicalTrials.gov/show/NCT03713619

  13. Muscianisi E, Potocki AC, Keefe D, Thomas N, Kasparek T, Kimball AB et al (2021) COVID-19 and treatment with biologics: Safety insights from the phase 3 studies of secukinumab in patients with moderate-to-severe hidradenitis suppurativa. Exp Dermatol 30(SUPPL 1):77–78

    Google Scholar 

  14. Tufts Medical C Exploratory Trial Evaluating Cosentyx (Secukinumab) for Patients With Moderate-to-Severe Hidradenitis Suppurativa 2018 [updated June 2019. https://ClinicalTrials.gov/show/NCT03099980

  15. Casseres RG, Prussick L, Zancanaro P, Rothstein B, Joshipura D, Saraiya A et al (2020) Secukinumab in the treatment of moderate to severe hidradenitis suppurativa: results of an open-label trial. J Am Acad Dermatol 82(6):1524–1526

    Article  CAS  PubMed  Google Scholar 

  16. Van der Zee H, de Ruiter L, Van Den Broecke D, Dik W, Laman J, Prens E (2011) Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)‐1β and IL‐10 in hidradenitis suppurativa skin: a rationale for targeting TNF‐α and IL‐1β. Br J Dermatol 164(6):1292–1298

    Article  PubMed  Google Scholar 

  17. Matusiak L, Bieniek A, Szepietowski JC (2009) Increased serum tumour necrosis factor-in Hidradenitis Suppurativa patients: is there a basis for treatment with Anti-tumour Necrosis Factor-α Agent’. Acta dermato-venereologica 89(6):601–603

    Article  CAS  PubMed  Google Scholar 

  18. Florida Academic Dermatology C Study to Assess the Safety and Efficacy of Infliximab to Treat Hidradenitis Suppurtativa 2008 [updated November 2008. https://ClinicalTrials.gov/show/NCT00795574

  19. Grant A, Gonzalez T, Montgomery MO, Cardenas V, Kerdel FA (2010) Infliximab therapy for patients with moderate to severe hidradenitis suppurativa: a randomized, double-blind, placebo-controlled crossover trial. J Am Acad Dermatol 62(2):205–217

    Article  CAS  PubMed  Google Scholar 

  20. Services Institute of Medical Sciences P Efficacy and Safety of Infliximab Biosimilar in Treatment of Resistant Hidradenitis Suppurativa 2023 [updated December 2022. https://ClinicalTrials.gov/show/NCT05663268

  21. Singh S, Proudfoot J, Xu R, Sandborn WJ (2018) Obesity and response to Infliximab in patients with inflammatory Bowel diseases: pooled analysis of individual participant data from clinical trials. Am J Gastroenterol 113(6):883–889

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Penn State U, Amgen Treatment of Hidradenitis Suppurativa Using Etanercept 2008 [updated November 2017. https://ClinicalTrials.gov/show/NCT00949546

  23. Adams DR, Yankura JA, Fogelberg AC, Anderson BE (2010) Treatment of hidradenitis suppurativa with etanercept injection. Arch Dermatol 146(5):501–504

    Article  CAS  PubMed  Google Scholar 

  24. University of P Etanercept for Treatment of Hidradenitis 2008 [updated January 2011 https://ClinicalTrials.gov/show/NCT00107991

  25. Lee RA, Dommasch E, Treat J, Sciacca-Kirby J, Chachkin S, Williams J et al (2009) A prospective clinical trial of open-label etanercept for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 60(4):565–573

    Article  PubMed  PubMed Central  Google Scholar 

  26. University of A Etanercept in Hidradenitis Suppurativa [updated May 2006. https://ClinicalTrials.gov/show/NCT00329823

  27. Giamarellos-Bourboulis E, Pelekanou E, Antonopoulou A, Petropoulou H, Baziaka F, Karagianni V et al (2008) An open‐label phase II study of the safety and efficacy of etanercept for the therapy of hidradenitis suppurativa. Br J Dermatol 158(3):567–572

    Article  CAS  PubMed  Google Scholar 

  28. Pelekanou A, Kanni T, Savva A, Mouktaroudi M, Raftogiannis M, Kotsaki A et al (2010) Long-term efficacy of etanercept in hidradenitis suppurativa: results from an open‐label phase II prospective trial. Exp Dermatol 19(6):538–540

    Article  CAS  PubMed  Google Scholar 

  29. Cusack C, Buckley C (2006) Etanercept: effective in the management of hidradenitis suppurativa. Br J Dermatol 154(4):726–729

    Article  CAS  PubMed  Google Scholar 

  30. Schlapbach C, Hänni T, Yawalkar N, Hunger RE (2011) Expression of the IL-23/Th17 pathway in lesions of hidradenitis suppurativa. J Am Acad Dermatol 65(4):790–798

    Article  CAS  PubMed  Google Scholar 

  31. University Medical Center G, Janssen-Cilag BV A Proof of Concept Study to Evaluate the Effectiveness of Ustekinumab in Hidradenitis Suppurativa 2014 [updated February 2015. https://ClinicalTrials.gov/show/NCT01704534

  32. Jonkman MF, Horváth B (2015) USTEKINUMAB IN HIDRADENITIS SUPPURATIVA: A CLINICAL OPEN LABEL STUDY WITH ANALYSES. HIDRADENITIS SUPPURATIVA. :79

  33. Kimball AB, Loesche C, Prens EP, Bechara FG, Weisman J, Rozenberg I et al (2022) IL-17A is a pertinent therapeutic target for moderate‐to‐severe hidradenitis suppurativa: combined results from a pre‐clinical and phase II proof‐of‐concept study. Exp Dermatol 31(10):1522–1532

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  34. Rockefeller U Molecular Characteristics of Brodalumab in Hidradenitis Suppurativa 2022 [updated July 27 2022. https://ClinicalTrials.gov/show/NCT04979520

  35. Rockefeller U, Valeant P, Biomarkers In Hidradenitis Suppurativa Participants Receiving Brodalumab 2020 [updated June 4 2020. https://ClinicalTrials.gov/show/NCT03960268

  36. Navrazhina K, Frew JW, Gilleaudeau P, Sullivan-Whalen M, Garcet S, Krueger JG (2021) Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. J Allergy Clin Immunol 147(6):2213–2224

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Navrazhina K, Frew JW, Grand D, Williams SC, Hur H, Gonzalez J et al (2022) Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. Br J Dermatol 187(2):223–233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Scheel CH, Abu Rached N, Gambichler T (2022) Interleukin-17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum. Br J Dermatol 187(2):138–139

    Article  CAS  PubMed  Google Scholar 

  39. Frew JW, Navrazhina K, Garcet S, Krueger J (2020) 880 targeted IL-17RA antagonism ameliorates histological and transcriptomic features of hidradenitis suppurativa: a proof of concept study. J Invest Dermatology 140(7):S115

    Article  Google Scholar 

  40. SRL UCBB, Pharma UCB A Study to Test the Efficacy, Safety and Pharmacokinetics of Bimekizumab in Subjects With Moderate to Severe Hidradenitis Suppurativa 2018 [updated April 2022. https://ClinicalTrials.gov/show/NCT03248531

  41. Glatt S, Jemec GB, Forman S, Sayed C, Schmieder G, Weisman J et al (2021) Efficacy and safety of bimekizumab in moderate to severe hidradenitis suppurativa: a phase 2, double-blind, placebo-controlled randomized clinical trial. JAMA Dermatology 157(11):1279–1288

    Article  PubMed  Google Scholar 

  42. Jemec GBE, Sayed C, Schmieder G, Weisman J, Rolleri R, Seegobin S et al (2020) Efficacy and safety of bimekizumab, a dual interleukin (IL)-17A and IL-17F inhibitor, for the treatment of moderate-to-severe hidradenitis suppurativa (HS): a 12-week, randomised, double-blind, placebo-controlled, phase 2 study. Exp Dermatol 29(SUPPL 1):31–32

    Google Scholar 

  43. SRL UCBB, Pharma UCB A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa 2021 [updated November 2022. https://ClinicalTrials.gov/show/NCT04242498

  44. SRL UCBB, Pharma UCB A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa 2024 [updated March 2023. https://ClinicalTrials.gov/show/NCT04901195

  45. SRL UCBB, Pharma UCB A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa 2022 [updated Februrary 2023. https://ClinicalTrials.gov/show/NCT04242446

  46. Inc A Hidradenitis Suppurativa Phase 2b Pivotal Study of Izokibep 2023 [updated February 2023. https://ClinicalTrials.gov/show/NCT05355805

  47. Novartis P, Novartis Efficacy, Safety, and Pharmacokinetics Study of CJM112 in Hidradenitis Suppurativa Patients 2016 [updated July 2022. https://ClinicalTrials.gov/show/NCT02421172

  48. Kimball A, Prens E, Bechara F, Weisman J, Kolbinger F, Rozenberg I et al (eds) (2019) Hidradenitis suppurativa responds to a novel anti-il17 antibody (CJM112) in a controlled clinical trial vs. placebo. 24th World Congress of dermatology, Milan

  49. Dajnoki Z, Somogyi O, Medgyesi B, Jenei A, Szabó L, Gáspár K et al (2022) Primary alterations during the development of hidradenitis suppurativa. J Eur Acad Dermatol Venereol 36(3):462–471

    Article  CAS  PubMed  Google Scholar 

  50. Barbara Horváth PI, Janssen-Cilag L, University Medical Center G Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study 2020 [updated August 2019. https://ClinicalTrials.gov/show/NCT04061395

  51. Dudink K, Bouwman K, Chen Y, DePrimo SE, Munoz-Elias EJ, Aarts P et al (2023) Guselkumab for Hidradenitis Suppurativa: a phase II, open label, mode of action study. Br J Dermatol. :ljad010

  52. Dudink K, Bouwman KS, Muñoz E, Sathaliya T, Aarts P, Schappin R et al (2022) Guselkumab for HS: a phase II open label, mode of action study. Exp Dermatol 31:74

    Google Scholar 

  53. Janssen R, Development LLC A Study to Evaluate the Efficacy, Safety, and Tolerability of Guselkumab for the Treatment of Participants With Moderate to Severe Hidradenitis Suppurativa (HS) 2020 [updated June 2021. https://ClinicalTrials.gov/show/NCT03628924

  54. AbbVie. A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa 2021 [updated August 2022. https://ClinicalTrials.gov/show/NCT03926169

  55. Kimball AB, Prens EP, Passeron T, Maverakis E, Turchin I, Beeck S et al (2023) Efficacy and safety of Risankizumab for the treatment of Hidradenitis Suppurativa: a phase 2, Randomized, Placebo-Controlled Trial. Dermatology Therapy. :1–13

  56. Thomi R, Yerly D, Yawalkar N, Simon D, Schlapbach C, Hunger R (2017) Interleukin-32 is highly expressed in lesions of hidradenitis suppurativa. Br J Dermatol 177(5):1358–1366

    Article  CAS  PubMed  Google Scholar 

  57. AnaptysBio I A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With Hidradenitis Suppurativa 2022 [updated February 2023. https://ClinicalTrials.gov/show/NCT04856930

  58. Boehringer I A Study to Test Whether Spesolimab Helps People With a Skin Disease Called Hidradenitis Suppurativa 2022 [updated September 2022. https://ClinicalTrials.gov/show/NCT04762277

  59. Boehringer I A Study Investigating Long-term Treatment With Spesolimab in People With a Skin Disease Called Hidradenitis Suppurativa Who Completed a Previous Clinical Trial 2024 [updated March 2023. https://ClinicalTrials.gov/show/NCT04876391

  60. Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood J Am Soc Hematol 117(14):3720–3732

    CAS  Google Scholar 

  61. Witte-Haendel E, Wolk K, Tsaousi A, Irmer ML, Moessner R, Shomroni O et al (2019) The IL-1 pathway is hyperactive in Hidradenitis Suppurativa and contributes to skin infiltration and Destruction. J Invest DERMATOLOGY 139(6):1294–1305

    Article  CAS  Google Scholar 

  62. Stergianou D, Tzanetakou V, Bolanou A, Kanni T, Micha S, Rellou S et al (2021) Cytokine profile of pus in patients with hidradenitis suppurativa (HS): how it is associated with treatment response to cytokine inhibitors. Exp Dermatol 30(SUPPL 1):87

    Google Scholar 

  63. Tzanetakou V, Kanni T, Giatrakou S, Katoulis A, Papadavid E, Netea MG et al (2016) Safety and Efficacy of Anakinra in severe Hidradenitis Suppurativa A Randomized Clinical Trial. JAMA DERMATOLOGY 152(1):52–59

    Article  PubMed  Google Scholar 

  64. University of California SF Anakinra as a Treatment for Hydradenitis Suppurativa 2013 [updated August 2014. https://ClinicalTrials.gov/show/NCT01516749

  65. Leslie KS, Tripathi SV, Nguyen TV, Pauli M, Rosenblum MD (2014) An open-label study of anakinra for the treatment of moderate to severe hidradenitis suppurativa. J Am Acad Dermatol 70(2):243–251

    Article  CAS  PubMed  Google Scholar 

  66. Janssen R, Development LLC A Study to Evaluate the Efficacy, Safety and Tolerability of Bermekimab in Patients With Hidradenitis Suppurativa 2020 [updated May 2021. https://ClinicalTrials.gov/show/NCT04019041

  67. Janssen R, Development LLC A Study of Bermekimab in Patients With Hidradenitis Suppurativa 2019 [updated March 2022. https://ClinicalTrials.gov/show/NCT03512275

  68. Gottlieb A, Natsis NE, Kerdel F, Forman S, Gonzalez E, Jimenez G et al (2020) A phase II open-label study of bermekimab in patients with hidradenitis suppurativa shows resolution of inflammatory lesions and pain. J Invest Dermatology 140(8):1538–1545 e2

    Article  CAS  Google Scholar 

  69. AbbVie A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy 2023 [updated March 2023. https://ClinicalTrials.gov/show/NCT05139602

  70. Liu H, Burn TC, Jackson J, Howell M, Santos LL, Alavi A et al (2021) 049 Janus Kinase 1 inhibitor INCB054707 modulates Disease-Associated markers and pathways in Hidradenitis Suppurativa. J Invest Dermatology 141(10):S157

    Article  Google Scholar 

  71. Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Liu H et al (2022) Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa: results from two phase II studies. Br J Dermatol 186(5):803–813

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Alavi A, Hamzavi I, Brown K, Santos LL, Zhu Z, Howell MD et al (2021) A randomized, placebo-controlled, phase 2 study of the Janus kinase 1 inhibitor INCB054707 for patients with moderate-to-severe hidradenitis suppurativa. Exp Dermatol 30:69–70

    Google Scholar 

  73. Incyte C A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa 2019 [updated August 13. https://ClinicalTrials.gov/show/NCT03607487

  74. Incyte C A Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa 2019 [updated April 22. https://ClinicalTrials.gov/show/NCT03569371

  75. Incyte C A Study to Evaluate the Efficacy and Safety of Povorcitinib (INCB054707) in Participants With Moderate to Severe Hidradenitis Suppurativa 2025 [updated March 11. https://ClinicalTrials.gov/show/NCT05620823

  76. University of Colorado D, National Institute of A, Musculoskeletal, Skin D. Tofacitinib for Immune Skin Conditions in Down Syndrome 2024 [updated January 2023. https://ClinicalTrials.gov/show/NCT04246372

  77. Dunnick CA, Rachubinski A, Enriquez-Estrada B, Worek K, Galbraith M, Smith K et al (2022) LB943 tofacitinib treatment of inflammatory skin conditions in patients with Down Syndrome. J Invest Dermatology 142(8):B16

    Article  Google Scholar 

  78. Savage KT, Santillan MR, Flood KS, Charrow A, Porter ML, Kimball AB (2020) Tofacitinib shows benefit in conjunction with other therapies in recalcitrant hidradenitis suppurativa patients. JAAD Case Rep 6(2):99–102

    Article  PubMed  PubMed Central  Google Scholar 

  79. AbbVie A Study of Oral Upadacitinib Tablet Compared to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa to Assess Change in Disease Symptoms 2021 [updated April 22. https://ClinicalTrials.gov/show/NCT04430855

  80. Incyte C Study to Evaluate of the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa 2023 [updated December 2022. https://ClinicalTrials.gov/show/NCT05635838

  81. Kirby SJ, Incyte C Topical Ruxolitinib 1.5% for Hidradenitis Suppurativa Treatment 2024 [updated December 2022. https://ClinicalTrials.gov/show/NCT04414514

Download references

Acknowledgements

None.

Funding

This research received no specific grant from any funding agency on the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Warren Alpert Medical School of Brown University, Providence, RI, USA

    Dorra Guermazi & Asghar Shah

  2. Department of Dermatology, Warren Alpert Medical School of Brown University, 593 Eddy St, APC 10, Providence, RI, 02905, USA

    Sara Yumeen & Elie Saliba

Authors
  1. Dorra Guermazi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Asghar Shah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sara Yumeen
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Elie Saliba
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All the authors have read and approved the final version of the manuscript. DG and AS wrote the main manuscript text. DG and AS prepared all figures and tables. ES and SY validated the project. ES and SY supervised, reviewed, and edited the manuscript.

Corresponding author

Correspondence to Elie Saliba.

Ethics declarations

Competing interests

The authors declare no competing interests.

Conflict of interests

The authors declare that there is no conflict of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Guermazi, D., Shah, A., Yumeen, S. et al. The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review. Arch Dermatol Res 316, 259 (2024). https://doi.org/10.1007/s00403-024-03121-x

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1007/s00403-024-03121-x

Keywords

Search

Navigation